Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 92

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part II, Item 1
Chunk 92
---
 license agreement could materially and adversely affect our
operations, financial condition, and results of operations.

Our
business and future prospects are significantly dependent on our exclusive, worldwide license agreement with Aquanova AG, which grants
us rights to develop, manufacture, distribute, and sell key products, including JOTROL™. Any adverse development related to this
agreement could materially and adversely affect our operations, financial condition, and results of operations

If
the license agreement with Aquanova AG were to be terminated, limited, or materially altered, we could lose access to essential proprietary
technologies, such as Aquanova’s NovaSOL® formulation technology, which is critical for the bioavailability and effectiveness
of our Nugevia brand. Disputes over contract terms, intellectual property rights, or performance obligations could result in costly litigation,
delays in product development, or loss of commercialization rights. Additionally, our obligation to pay license fees and royalties under
the license agreement represents a significant financial commitment, and any inability to meet these obligations could jeopardize our
rights under the license agreement. The loss or impairment of this license would require us to seek alternative technologies or partners,
which may not be available on favorable terms, if at all, and could delay or prevent the development and commercialization of our products.

Should
we fail to maintain a productive relationship with Aquanova or if Aquanova experiences operational or financial difficulties, our ability
to deliver products to market could be compromised, negatively impacting our growth prospects and competitive position.

If
the Company or its suppliers fails to comply with FDA or other regulations, it could result in enforcement actions or delays in the Nugevia
brand product launch.

The
Company is subject to various federal, state, and local laws, regulations and administrative practices that affect its business. Our
suppliers and contract manufacturers are also subject to such laws and regulations. The safety, formulation, manufacturing, processing,
packaging, importation, labeling, promotion, advertising, and distribution of the Nugevia brand products are subject to regulation by
several federal agencies, including the FDA, the FTC, the USDA, the CPSC and the EPA, as well as by various state and local agencies.
If these laws and regulations were violated by our management, suppliers or distributors, we could be subject to regulatory enforcement
action, public warning letters, product recalls, fines, penalties and sanctions, including injunctions against the future shipment and
sale of products, restitution and disgorgement of profits, operating restrictions. In